triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer#875166ClinicalTrials.gov
• LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer#325279ClinicalTrials.gov
• Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer#966339ClinicalTrials.gov
• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer#1009580ClinicalTrials.gov
• Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer#844618ClinicalTrials.gov
• Onvansertib + Paclitaxel In TNBC#890749ClinicalTrials.gov
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC#832162ClinicalTrials.gov
• Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery#1030882ClinicalTrials.gov
• Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer#910366ClinicalTrials.gov
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)#261467ClinicalTrials.gov
• Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study#981832ClinicalTrials.gov
• Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy#890876ClinicalTrials.gov
• Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients#825535ClinicalTrials.gov
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)#898300ClinicalTrials.gov
• Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases#995141ClinicalTrials.gov
• Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC#900896ClinicalTrials.gov
• Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer#349969ClinicalTrials.gov
• Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer#918211ClinicalTrials.gov
• Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer#879570ClinicalTrials.gov
• Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer#825106ClinicalTrials.gov
• Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer#880867ClinicalTrials.gov
• An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy#26106HAL (France)
• SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)#121344ClinicalTrials.gov
• Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer#826495ClinicalTrials.gov
• Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)#912754ClinicalTrials.gov
• Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer#871400ClinicalTrials.gov
• Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer#839128ClinicalTrials.gov
• A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy#918722ClinicalTrials.gov
• Hsp27 downregulation decreases β-catenin expression and sensitizes triple-negative breast cancer cells to doxorubicin#405939IRIS
• SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer#903348ClinicalTrials.gov
• Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer#982679ClinicalTrials.gov
• A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients#1031046ClinicalTrials.gov
• CMV seropositivity associates with poor clinical outcome in triple negative breast cancer#121889HAL (France)
• Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer#810489ClinicalTrials.gov
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer#833610ClinicalTrials.gov
• Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients#828346ClinicalTrials.gov
• Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)#914899ClinicalTrials.gov
• Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer#174872ClinicalTrials.gov
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype#852837ClinicalTrials.gov
• Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer#992131ClinicalTrials.gov
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer#332737ClinicalTrials.gov
• L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients#841146ClinicalTrials.gov
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer#432885ClinicalTrials.gov
• Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer#887657ClinicalTrials.gov
• QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy#300263ClinicalTrials.gov
• Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study#869312ClinicalTrials.gov
• Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women#904211ClinicalTrials.gov
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer#181765ClinicalTrials.gov
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer#268031ClinicalTrials.gov
• DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer#268093ClinicalTrials.gov